Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma

Safety and Efficacy of Orelabrutinib（O） in Combination With Thiotepa（T） in Refractory and Relapsed Primary CNS Lymphoma： A Single-arm, Multicenter Phase Ib/II Study（OT）

The purpose of this study was to investigate the maximum tolerated dose and efficacy of Orelabrutinib combined with Thiotepa in refractory and relapsed primary central nervous system lymphoma (PCNSL).

Study Overview

• Status: Not yet recruiting
• Conditions: Non Hodgkin Lymphoma; PCNSL; Refractory and Relapsed Primary CNS Lymphoma
• Intervention / Treatment: Drug: Orelabrutinib; Drug: Orelabrutinib; Drug: Thiotepa

• Study Type: Interventional
• Enrollment (Anticipated): 29
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Guangdong
    • Guangzhou, Guangdong, China, 510060
      • Department of Medical Oncology, Sun Yat-Sen University Cancer Center
      • Principal Investigator: Huiqiang Huang

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Men and woman who aged 18 or older on the day of consenting to the study.
2. Participants must be able to understand and willing to sign a written informed consent document.
3. ECOG performance status of 0 to 2.
4. Histologically documented primary central nervous system(CNS) lymphoma.
5. Participants should have evidence of 1 measurable or evaluable enhancing disease on MRI, PET-CT or PET-MRI.
6. Relapsed or refractory disease with at least 1 prior HD-MTX-based therapy.
7. Life expectancy of > 3 months (in the opinion of the investigator).
8. Any non-hematologic toxicity associated with prior treatment should be stable and recovered to ≤ Grade 1 (according to NCI CTCAE V5.0，except for alopecia)

9. Demonstrate adequate organ function as defined below: (all screening labs should be performed within 14 days of treatment initiation)

   • Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L, Platelets ≥ 75 x 10^9/L，Hb ≥80 g/L;
   • International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤1.5 times the upper limit of normal;
   • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal;
   • Serum bilirubin ≤ 1.5 times the upper limit of normal;
   • Creatinine clearance ≥ 60 mL/min calculated by the Cockcroft-Gault formula using actual body weight.
10. Must be able to tolerate MRI/CT/PET-CT/PET-MRI scans and lumbar puncture.
11. Ability to swallow oral medications.
12. Participants must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, and other requirements of the study.
13. If the disease progresses after radiotherapy, there is no need for washout period;If the tumor responds after radiotherapy, a 6-month washout period is required.
14. First-line treatment with thiotepa-containing regimens is effective, and patients who relapse after more than 1 year can be enrolled.

Exclusion Criteria:

1. The pathological diagnosis was T-cell lymphoma.
2. Prior therapy with a checkpoint inhibitor or BTK inhibitor.
3. Participation in another clinical study with an investigational product during the 12 weeks prior to the first day of study treatment.
4. Participants requires more than 5 mg of dexamethasone daily or the equivalent for control of primary CNS symptoms lasting for more than 5 days within 14 days.
5. Active bleeding within 4 weeks prior to first administration, or ongoing use of anticoagulant/antiplatelet agents, or tendency to bleeding (e.g., esophageal varices at risk for bleeding, locally active ulcerative lesions) or coagulation disorder as considered by the investigator.

6. Has an uncontrolled or significant cardiovascular disease, including (but not limited to) :

   • Any of the following conditions within 6 months prior to initial administration: congestive heart failure (NYHA class III or IV), myocardial infarction, unstable angina, or arrhythmia requiring treatment at the time of screening, left ventricular ejection fraction (LVEF) <50%;
   • Primary or secondary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmic right ventricular cardiomyopathy, restricted cardiomyopathy, undefined cardiomyopathy);
   • Clinical history of prolonged QTc phase, grade II type II atrioventricular block or grade III atrioventricular block or QTc interval (F method) & GT;470 msec (female) or >;480msec (male).
   • Hypertension, which is difficult to control, is not suitable for this study
7. Uncontrolled infections or infections requiring intravenous antimicrobial treatment.
8. Known active infection with hepatitis C virus (HCV)，hepatitis B virus (HBV) or syphilis as determined by serologic tests and/or PCR.
9. History of or positive human immunodeficiency virus (HIV) screen result.
10. Patient underwent major systemic surgery ≤ 6 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug.
11. Previous organ transplantation or allogeneic stem cell transplantation.
12. Pregnant or lactating women, or subjects of childbearing age who do not want to use contraception for 180 days from the study period to the end of the study.
13. History of stroke and intracranial hemorrhage within 6 months before the first administration, except intracranial hemorrhage caused by surgical sequelae.
14. Patient with hepatic、renal 、neurological、psychiatric, or endocrine disease , as Investigator's discretion, is too damaged to participate in this study; Patient having other conditions that should exclude it from the trial, as the Investigator's discretion.
15. Alcohol or drug abuse.
16. Allergic to any component of the investigational product.
17. Participants who received live viral vaccination within 4 weeks from enrollment date. Patients are prohibited from receiving live attenuated vaccines, including influenza vaccines, during the study period.
18. Previous CAR-T therapy.
19. PVRL.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Phase Ib; Orelabrutinib dose escalation will occur using a standard 3+3 dose-escalation approach to determined the maximum tolerated dose(MTD) of orelabrutinib dose in combined with thiotepa, beginning at dose level I (150 mg daily) and potentially escalating to dose level 2 (200mg) with rules for escalation and de-escalation. If the dose-limiting toxicity is not found, the dose of 200mg will be used for phase II trial (RP2D). Orelabrutinib: 150mg or 200mg orally daily. Thiotepa: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle).	Drug: Orelabrutinib; 150mg or 200mg orally daily; Drug: Orelabrutinib; RP2D; Drug: Thiotepa; 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)
Experimental: Phase II; Participants will receive orelabrutinib and thiotepa at the pre-determined dosage level established in Phase 1b, until progression of the disease (PD), unacceptable toxicity, or patient/investigator discretion. The response will be evaluated every 2 cycles. Orelabrutinib: RP2D (150 mg or 200 mg qd) Thiotepa:Sintilimab: The dose of thiotepa is fixed as 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle).	Drug: Orelabrutinib; 150mg or 200mg orally daily; Drug: Orelabrutinib; RP2D; Drug: Thiotepa; 30 mg/m2 intravenously every 3 weeks (maximum 6 cycle)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1 Dose Escalation：The maximum tolerated dose (MTD)	To determine the maximum tolerated dose (MTD)	Incidence of dose limiting toxicities (DLTs) up to 21 days
Part 2 Dose Expansion：ORR (Investigator-Assessed)	The overall response rate (ORR) including complete response (CR), unconfirmed complete (CRu) and partial response (PR) according to the 2005 Response Criteria of the International Primary CNS Lymphoma Collaborative Group (IPCG)	Up to 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Part 1 Dose Escalation：Objective response rate (ORR)	The objective response rate (ORR) is defined as the proportion of patients with a best response of CR, CRu or PR	Up to 2 years
Part 1 Dose Escalation：Compelet response rate (CRR)	The complete response rate (ORR) is defined as the proportion of patients with a best response of CR or CRu	Up to 2 years
Part 1 Dose Escalation：Duration of overall response (DOR)	The duration of overall response is measured from the time measurement	Up to 2 years
Part 1 Dose Escalation：Disease control rate (DCR)	The disease control rate (DCR) is defined as the proportion of patients with a best response of CR, CRu, PR or SD	Up to 2 years
Part 1 Dose Escalation：Progression-free survival (PFS)	The progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first	Up to 2 years
Part 1 Dose Escalation：Overall survival (OS)	The overall survival (OS) is defined as the duration of time from start of treatment to time of death.	Up to 2 years
Part 2 Dose Expansion：Compelet response rate (CRR)	The complete response rate (ORR) is defined as the proportion of patients with a best response of CR or CRu	Up to 2 years
Part 2 Dose Expansion：Duration of overall response (DOR)	The duration of overall response is measured from the time measurement	Up to 2 years
Part 2 Dose Expansion：Disease control rate (DCR)	The disease control rate (DCR) is defined as the proportion of patients with a best response of CR, CRu, PR or SD	Up to 2 years
Part 2 Dose Expansion：Progression-free survival (PFS)	The progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first	Up to 2 years
Part 2 Dose Expansion：Overall survival (OS)	The overall survival (OS) is defined as the duration of time from start of treatment to time of death.	Up to 2 years
The toxicity profile of the orelabrutinib and thiotepa combination therapy	All subjects who received at least one dose of OT will be included in the safety analysis. Adverse events will be graded by the investigator according to the NCI-CTCAE Version 5.0.	Up to 2 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Describe the tumor mutation profile by NGS	DNA from tumor tissue and CSF will be sequencing by next generation sequencing (NGS).Identify the PNCSL-related variants and gene expression alterations by NGS.	Up to 2 years

Collaborators and Investigators

• Sponsor: Huiqiang Huang
• Collaborators: Guangdong 999 Brain Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2021
• Primary Completion (Anticipated): December 1, 2022
• Study Completion (Anticipated): June 1, 2024

Study Registration Dates

• First Submitted: August 16, 2021
• First Submitted That Met QC Criteria: August 19, 2021
• First Posted (Actual): August 26, 2021

Study Record Updates

• Last Update Posted (Actual): August 26, 2021
• Last Update Submitted That Met QC Criteria: August 19, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: PCNSL
• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Thiotepa
• Other Study ID Numbers: OT

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No